X Lab Series · Preparation process
Chimeric antigen receptor T cells,engineered on an automated line.
CAR-T cells are a patient’s own T cells, engineered with a chimeric antigen receptor to target cancer. CellAuto automates the whole preparation, from apheresis through activation, transduction and expansion to a released product.
Overview
What they are
CAR-T cells are T cells engineered to carry a chimeric antigen receptor so they recognise and attack cancer cells. They are one of the most important advances in cancer cell therapy.
Why automate it
CAR-T manufacturing is a long, multi-step, single-patient process where every batch matters. A closed automated line reduces contamination risk and keeps each patient’s batch consistent.
Where it is used
Haematological malignancies such as leukaemia and lymphoma, with solid-tumour applications under active investigation.
The automated process
The steps above follow CellAuto’s standard automated CAR-T workflow. Activation, transduction and release criteria are configured and validated for each specific product and site.
Core platform systems
Every transfer between steps is made through a closed, aseptic connection, so the cells stay in a sealed path from start to finish. The exact configuration is agreed during project planning.
Bring this processonto an automated line.
Tell us the cell type, the batch size and the facility, and we will tell you what the automated preparation looks like for you.